The stock of Altimmune Inc. (NASDAQ:ALT) decreased by -$0.05 on Friday to finish at $2.40, down -2.04 percent. The last five days have seen an average of 736,800 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$14.05. The average number of shares traded over the last 20 days was 1,140,215, while the average volume over the last 50 days totaled 1,792,484.
ALT stock dropped -19.73% since last month. On 08/25/23, the company’s shares reached a one-month low of $2.39. The stock touched a high of $23.49 on 01/13/23, after rallying from a low of $2.44 in 52 weeks. The price of ALT stock has declined by -85.41% or -$14.05 this year, reaching a new high 3 times. Still, the stock price is down -89.78% from the 52-week high.
Insider Transactions
ALT stock investors should be aware that Altimmune Inc. (ALT) stock had its last reported insider trading activity 13 days ago on Aug 15. On Aug 15, Director Drutz David acquired 300 shares at $2.88 each. This transaction resulted in the insider spending $862. On Mar 24, Eisenstadt Richard I added 10,000 shares at a price of US$4.31. After the transaction, the insider now owns 22,010 shares. Chief Medical Officer Harris Matthew Scott had earlier bought 10,000 shares on Mar 23 for $4.22 a share. The transaction was completed for $42,200.
Financial Health
For the three months ended June 29, Altimmune Inc.’s quick ratio was 14.80, while its current ratio was 14.80, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $87.67 million and revenue of $68000.0.
Earnings Surprise
According to Altimmune Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $10000.0, while revenues fell by -3300.0% to $20000.0. It was predicted that Altimmune Inc.’s quarterly earnings would be -$0.32, but it ended up being -$0.46, beating the consensus by 30.40%. EBITDA was -$18.51 million for the quarter. At the end of Altimmune Inc.’s most recent quarter ended June 29, its liabilities totaled 15.6 million, while its total debt was $0.9 million. Equity owned by shareholders amounts to $52.69 million.
Technical Picture
Here’s a quick look at Altimmune Inc.’s (ALT) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 16.58%, suggesting the stock is oversold, with a 21.72% historical volatility rate.
The stochastic %K and %D were 2.84% and 4.82% respectively, while the average true range (ATR) was 0.15. Based on the 14-day stochastic reading of 1.04%, the RSI (14) reading is 22.68%. On the 9-day MACD Oscillator, the stock is at -0.13, and the 14-day reading is at -0.28.
Analyst Ratings
Altimmune Inc. (NASDAQ: ALT) was downgraded by Goldman to a a Neutral rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned Altimmune Inc. (ALT) an Buy rating. ALT is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is ALT’s price target for the next 12 months?
The current consensus forecast for the stock is between $6.00 and $35.00, with a median target price of $15.00. In analyzing these forecasts, the average price target given by analysts for Altimmune Inc. (ALT) is $19.43.
